Effect of renal replacement therapy on selected arachidonic acid derivatives concentration
- PMID: 32917166
- PMCID: PMC7488457
- DOI: 10.1186/s12882-020-02053-8
Effect of renal replacement therapy on selected arachidonic acid derivatives concentration
Abstract
Background: Platelet activation is an important side effect of dialysis, resulted in a subsequent release of arachidonic acid (AA) from activated platelets. AA is involved in many pathologic conditions, such as inflammation, asthma, cancer, diabetes, hypertension, and the pathogenesis of kidney disease. The aim of this study was to define whether the dialysis type affects the concentration of AA derivatives in patients with chronic kidney disease.
Methods: 117 patients were qualified to the study group. Based on the type of renal replacement therapy, patients were divided into the following groups: hemodialysis (HD A - before/HD B - after hemodialysis), peritoneal dialysis (PD), kidney transplant patients (TE - before/TE A - after transplantation) and conservative treatment (CT) (30; 30; 27; 30 patients, respectively). The control group consisted of 30 healthy volunteers (NK). The ELISA methods were used to measure the concentrations of TXB2, 5-HETE, 12-HETE, and 15-HETE in the blood serum.
Results: Renal replacement therapy significantly influences the concentration of TXB2 (mean ± SD [ng/mL]: HD A- 34.6 ± 9; HD B- 28.3 ± 15.2; PD- 28.3 ± 15.2; CT- 34.2 ± 8.0; TE- 36.7 ± 42.9; TE A- 27.9 ± 8.8; NK- 19.6 ± 15; p = 0.010), 5-HETE (mean ± SD [ng/mL]: HD A- 284.2 ± 428.4; HD B- 304.8 ± 516.2; PD - 530.0 ± 553.3; CT- 318.7 ± 366.0; TE- 525.6 ± 358.0; TE A - 409.8 ± 377.1; NK 838.1 ± 497.8; p < 0.001) and 15-HETE (HD A-18.1 ± 8.7; HD B- 42.2 ± 14; PD - 36.3 ± 13.8; CT- 33.7 ± 14.0; TE- 19.5 ± 10.2; TE A - 34.4 ± 16.3; NK 22.2 ± 17.8; p < 0,001). There was a significant relationship between the type of renal replacement therapy and the duration of dialysis, and the concentration of TXB2, 12-HETE acid, and 15-HETE.
Conclusions: The type of renal replacement therapy significantly affects the concentration of AA derivatives. Peritoneal dialysis is the best method of dialysis, taking into account the concentration of arachidonic acid derivatives.
Keywords: 12-HETE; 15-HETE; 5-HETE; Chronic kidney disease; Kidney transplantation; Renal replacement therapy; Thromboxane B2.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures



Similar articles
-
Bioactive lipids derived from arachidonic acid metabolism in different types of renal replacement therapy.Chem Phys Lipids. 2017 Aug;206:71-77. doi: 10.1016/j.chemphyslip.2017.05.003. Epub 2017 May 19. Chem Phys Lipids. 2017. PMID: 28533146
-
[The level of thromboxane A2 and prostacyclin in patients with chronic kidney failure undergoing hemodialysis].Ter Arkh. 1991;63(6):66-8. Ter Arkh. 1991. PMID: 1948751 Russian.
-
The differences in 12-hydroxyeicosatetraenoic acid and thromboxane B2 release from guinea pig platelets.Prostaglandins. 1991 Nov;42(5):431-40. doi: 10.1016/0090-6980(91)90034-d. Prostaglandins. 1991. PMID: 1763200
-
[Renal replacement therapy by hemodialysis: an overview].Nephrol Ther. 2009 Jul;5(4):306-12. doi: 10.1016/j.nephro.2009.03.001. Epub 2009 May 28. Nephrol Ther. 2009. PMID: 19481513 Review. French.
-
Twice-weekly and incremental hemodialysis treatment for initiation of kidney replacement therapy.Am J Kidney Dis. 2014 Aug;64(2):181-6. doi: 10.1053/j.ajkd.2014.04.019. Epub 2014 May 17. Am J Kidney Dis. 2014. PMID: 24840669 Free PMC article. Review.
Cited by
-
The metabolomics analysis of cecal contents elucidates significant metabolites involved in the therapeutic effects of total flavonoids derived from Sonchus arvensis L. in male C57BL/6 mice with ulcerative colitis.Heliyon. 2024 Jun 16;10(12):e32790. doi: 10.1016/j.heliyon.2024.e32790. eCollection 2024 Jun 30. Heliyon. 2024. PMID: 39005925 Free PMC article.
-
Application of Nanomaterial-Mediated Ferroptosis Regulation in Kidney Disease.Int J Nanomedicine. 2025 Feb 5;20:1637-1659. doi: 10.2147/IJN.S496644. eCollection 2025. Int J Nanomedicine. 2025. PMID: 39931533 Free PMC article. Review.
-
The Nephrotoxin Puromycin Aminonucleoside Induces Injury in Kidney Organoids Differentiated from Induced Pluripotent Stem Cells.Cells. 2022 Feb 11;11(4):635. doi: 10.3390/cells11040635. Cells. 2022. PMID: 35203286 Free PMC article.
References
-
- Szczeklik A. (red), Diseases of the kidneys of the urinary tract. Acute in the kidney and chronic kidney disease. Kraków: Interna Szczeklika, Medycyna Praktyczna; 2017. pp. 1443–1461.
-
- Dudzik M, Deeg P, Raczak G. The influence of the inflammatory process on changes in the circulatory system of patients with chronic kidney disease. Cardiol Poland. 2009;67:10.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical